UK Chemists Call for Better Regulation of CBD Products

December 16, 2019 16:00:48

Very few products can claim to have risen from obscurity to extreme popularity as quickly as cannabidiol (CBD) has. The hemp extract is all the rage these days, and if you have been paying attention to the news, you’ve undoubtedly heard of it. The compound is extracted from industrial hemp, cannabis with minuscule levels of THC, and used in a variety of applications.

Undoubtedly, one of CBD’s most attractive aspects is its medicinal properties. Cannabidiol is one of the most potent and versatile natural medicines at the moment, and it’s used against a variety of diseases. For the past few years, users have used it with great success against anxiety, insomnia, high blood pressure and a plethora of other medical conditions.

Last year, the U.S. Food and Drug Administration approved a CBD based drug to treat seizures in rare and hard to manage pediatric epilepsies.

However, there’s still very little concrete research on the efficacy and side effects of the compound. Still, the market is flooded with tons of CBD products, with grocery stores, pharmacies and major retail chains carrying CBD products.

According to the National Pharmacy Association, CBD products need clearer information and better checks on content. The association represents hundreds of independent pharmacies.

Jasmine Shah from the association says that an increasing number of pharmacies are stocking CBD products despite the fact that there is very limited research on the safety and efficacy of the products at the moment. She says that pharmacists would like “clear authoritative guidance which makes it easy for health professionals, consumers and patients to make informed choices.”

CBD is classified as a food supplement in the UK, placing it under the Food Standards Agency. Since it’s still a fairly new product, the FSA has granted a grace period where CBD products will be allowed on the shelves as long as manufacturers give specific information about their products.

This includes contents, purity levels, and manufacturing practices. The FSA claims that despite providing CBD companies more than enough time, they haven’t gotten enough concrete data that would help in drawing up a framework for regulation.

Shah adds that due to the current state of uncertainty surrounding CBD products, pharmacists will have to rely on their own discretion. “It’s for each pharmacist to decide whether it is suitable to stock a CBD product or not, but in terms of the safety and efficacy of it more research is required.”

Analysts in the U.S. find the concerns of the UK chemists no different from what cannabidiol companies in North America, such as LiveWire Ergogenics Inc. (OTC: LVVV) and Marijuana Company of America Inc. (OTCQB: MCOA), have been pushing for from regulators.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.